Maura Gillison's HPV discovery transformed head and neck cancer treatment

Maura L. Gillison changed the question doctors asked about throat cancer. Instead of treating most head and neck cancers as a single disease driven mainly by cigarettes and alcohol, she helped establish that human papillomavirus causes a distinct subset, including oropharyngeal cancers, with consequences that still shape prevention, diagnosis and patient counseling.

The paper that changed the field

In 2000, Gillison coauthored the landmark Journal of the National Cancer Institute paper, Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. The study analyzed tumor tissue from 253 patients with newly diagnosed or recurrent head and neck squamous cell carcinoma, and its authors included Wayne M. Koch, Randolph B. Capone, Michael Spafford, William H. Westra, Li Wu, Marianna L. Zahurak, Richard W. Daniel, Michael Viglione, David E. Symer, Keerti V. Shah and David Sidransky.

That paper, published in volume 92 of the journal on pages 709 to 720, concluded that HPV was etiologically linked to a subset of head and neck cancers. Its impact was immediate and durable because it gave clinicians a biologic explanation for a cancer category that had long been discussed almost entirely through tobacco and alcohol exposure.

How the medical narrative changed

Before Gillison’s work, the public story of throat cancer was often narrowed to smoking and heavy drinking. Her research did not erase those causes, which remain important in head and neck oncology, but it forced the field to recognize that HPV-related disease was different enough to be considered on its own terms. That distinction mattered most for oropharyngeal cancers, where HPV became central to how doctors classify, explain and study the disease.

The change reached beyond pathology reports. Once HPV was recognized as a cause, doctors had a clearer way to talk to patients whose cancers were not tied to the familiar risk factors of tobacco or alcohol. That shift reduced the moral weight that many patients carried into the exam room and replaced blame with a more precise explanation of biology. Later oncology tributes described Gillison as a pioneer who transformed the treatment of mouth and throat cancers and spared patients from needless treatment, language that reflects how much the field changed after her findings took hold.

Why the discovery mattered for prevention and diagnosis

Gillison’s work helped move HPV from a virus associated mainly with anogenital cancers into the center of cancer prevention conversations more broadly. By showing that HPV could drive a subset of head and neck squamous cell carcinomas, the research strengthened the case for vaccination as a cancer-prevention tool, not only for cervical disease but also for cancers in the throat.

It also changed diagnosis. Tumors were no longer viewed as interchangeable simply because they appeared in the head and neck region. Clinicians could begin to separate HPV-associated cancers from tumors driven by other exposures, a shift that influenced how patients were informed about prognosis, testing and the biology of their disease. In practical terms, Gillison helped move head and neck oncology toward a more tailored conversation, one that could account for a viral cause rather than treating every case as the same disease with the same origin story.

Recognition from oncology institutions

Gillison’s influence was recognized across major cancer institutions. The University of Texas MD Anderson Cancer Center identified her as a distinguished, endowed professor of medicine in the Department of Thoracic/Head and Neck Medical Oncology in Houston, placing her at the center of a specialty she had helped redefine. ASCO later marked her as a Karnofsky Award recipient and a pioneer in HPV-associated cancers, underscoring how fully her discoveries had entered mainstream oncology.

Other tributes followed the same line. Damon Runyon published a remembrance on August 7, 2026, and The Cancer Letter, along with other oncology outlets, wrote about her influence on cancer research. Giants of Cancer Care highlighted the 2000 paper as the seminal work that established the link between HPV and oropharyngeal cancers, while Johns Hopkins University materials summarized the study’s retrospective effort to investigate HPVs in a large series of head and neck squamous cell carcinoma patients.

The legacy doctors still work with

Gillison’s legacy is not only that HPV belongs in the story of throat cancer. It is that the story itself became more accurate, more humane and more useful. A disease once discussed mainly through smoking and alcohol now has a better-defined viral pathway, a stronger prevention framework and a clinical vocabulary that lets doctors speak to patients with more precision and less stigma.

That shift still shapes how head and neck cancer is explained in clinics, how researchers design studies and how public health advocates argue for vaccination. Gillison changed the frame, and once the frame changed, everything inside it became easier to see.